ZNTL

Zentalis Pharmaceuticals, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$2.64

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30

Non-compliant assets / Total market cap %29.8 / %30

Non-compliant income / Total income %0 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.